Gain of Interaction with IRS1 by p110α-Helical Domain Mutants Is Crucial for Their Oncogenic Functions

Cancer Cell

Volumn 23, Issue 5, 2013, Pages 583-593

  Hao, Yujun ^a,d   Wang, Chao ^a,d,i   Cao, Bo ^a,e   Hirsch, Brett M ^f,j   Song, Jing ^b   Markowitz, Sanford D ^c,d   Ewing, Rob M ^b   Sedwick, David ^c,d   Liu, Lili ^c,d   Zheng, Weiping ^f,g   Wang, Zhenghe ^a,d,h  

^a Department of Genetics and Genome Sciences ^*  (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e THIRD MILITARY MEDICAL UNIVERSITY   (China)

^f UNIVERSITY OF AKRON   (United States)

^g JIANGSU UNIVERSITY   (China)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^j ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IRS1 PROTEIN; MUTANT PROTEIN; PEPTIDES AND PROTEINS; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P110; PROTEIN P85; UNCLASSIFIED DRUG;

ALPHA HELIX; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARCINOGENESIS; CELL MEMBRANE; COLORECTAL CANCER; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MAMMAL CELL; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84877819562     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.03.021     Document Type: Article

References (33)

1. Amzel L.M., Huang C.H., Mandelker D., Lengauer C., Gabelli S.B., Vogelstein B. Structural comparisons of class I phosphoinositide 3-kinases. Nat. Rev. Cancer 2008, 8:665-669.
2. Bachman K.E., Argani P., Samuels Y., Silliman N., Ptak J., Szabo S., Konishi H., Karakas B., Blair B.G., Lin C., et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 2004, 3:772-775.
3. Broderick D.K., Di C., Parrett T.J., Samuels Y.R., Cummins J.M., McLendon R.E., Fults D.W., Velculescu V.E., Bigner D.D., Yan H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 2004, 64:5048-5050.
4. Burke J.E., Perisic O., Masson G.R., Vadas O., Williams R.L. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc. Natl. Acad. Sci. USA 2012, 109:15259-15264.
5. Campbell I.G., Russell S.E., Choong D.Y., Montgomery K.G., Ciavarella M.L., Hooi C.S., Cristiano B.E., Pearson R.B., Phillips W.A. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004, 64:7678-7681.
6. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
7. Chakrabarty A., Rexer B.N., Wang S.E., Cook R.S., Engelman J.A., Arteaga C.L. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene 2010, 29:5193-5203.
8. Du Z., Song J., Wang Y., Zhao Y., Guda K., Yang S., Kao H.Y., Xu Y., Willis J., Markowitz S.D., et al. DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination. Sci. Signal. 2010, 3:ra80.
9. Essmann F., Schulze-Osthoff K. Translational approaches targeting the p53 pathway for anticancer therapy. Br. J. Pharmacol. 2012, 165:328-344.
10. Hemmings B.A., Restuccia D.F. PI3K-PKB/Akt pathway. Cold Spring Harb. Perspect. Biol. 2012, 4:a011189.
11. Huang C.H., Mandelker D., Schmidt-Kittler O., Samuels Y., Velculescu V.E., Kinzler K.W., Vogelstein B., Gabelli S.B., Amzel L.M. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 2007, 318:1744-1748.
12. Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J., Lee S.H. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24:1477-1480.
13. Levine D.A., Bogomolniy F., Yee C.J., Lash A., Barakat R.R., Borgen P.I., Boyd J. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin. Cancer Res. 2005, 11:2875-2878.
14. Li V.S., Wong C.W., Chan T.L., Chan A.S., Zhao W., Chu K.M., So S., Chen X., Yuen S.T., Leung S.Y. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 2005, 5:29.
15. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8:627-644.
16. Mandelker D., Gabelli S.B., Schmidt-Kittler O., Zhu J., Cheong I., Huang C.H., Kinzler K.W., Vogelstein B., Amzel L.M. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc. Natl. Acad. Sci. USA 2009, 106:16996-17001.
17. Miled N., Yan Y., Hon W.C., Perisic O., Zvelebil M., Inbar Y., Schneidman-Duhovny D., Wolfson H.J., Backer J.M., Williams R.L. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 2007, 317:239-242.
18. Oda K., Stokoe D., Taketani Y., McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005, 65:10669-10673.
19. Pacold M.E., Suire S., Perisic O., Lara-Gonzalez S., Davis C.T., Walker E.H., Hawkins P.T., Stephens L., Eccleston J.F., Williams R.L. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 2000, 103:931-943.
20. Pang H., Flinn R., Patsialou A., Wyckoff J., Roussos E.T., Wu H., Pozzuto M., Goswami S., Condeelis J.S., Bresnick A.R., et al. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res. 2009, 69:8868-8876.
21. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
22. Samuels Y., Diaz L.A., Schmidt-Kittler O., Cummins J.M., Delong L., Cheong I., Rago C., Huso D.L., Lengauer C., Kinzler K.W., et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7:561-573.
23. Vadas O., Burke J.E., Zhang X., Berndt A., Williams R.L. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci. Signal. 2011, 4:re2.
24. Vasudevan K.M., Barbie D.A., Davies M.A., Rabinovsky R., McNear C.J., Kim J.J., Hennessy B.T., Tseng H., Pochanard P., Kim S.Y., et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009, 16:21-32.
25. Walensky L.D., Kung A.L., Escher I., Malia T.J., Barbuto S., Wright R.D., Wagner G., Verdine G.L., Korsmeyer S.J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004, 305:1466-1470.
26. White A.W., Westwell A.D., Brahemi G. Protein-protein interactions as targets for small-molecule therapeutics in cancer. Expert Rev. Mol. Med. 2008, 10:e8.
27. Yu J., Becka S., Zhang P., Zhang X., Brady-Kalnay S.M., Wang Z. Tumor-derived extracellular mutations of PTPRT /PTPrho are defective in cell adhesion. Mol. Cancer Res. 2008, 6:1106-1113.
28. Zhang X., Guo A., Yu J., Possemato A., Chen Y., Zheng W., Polakiewicz R.D., Kinzler K.W., Vogelstein B., Velculescu V.E., Wang Z.J. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc. Natl. Acad. Sci. USA 2007, 104:4060-4064.
29. Zhang X., Guo C., Chen Y., Shulha H.P., Schnetz M.P., LaFramboise T., Bartels C.F., Markowitz S., Weng Z., Scacheri P.C., Wang Z. Epitope tagging of endogenous proteins for genome-wide ChIP-chip studies. Nat. Methods 2008, 5:163-165.
30. Zhang P., Zhao Y., Zhu X., Sedwick D., Zhang X., Wang Z. Cross-talk between phospho-STAT3 and PLCγ1 plays a critical role in colorectal tumorigenesis. Mol. Cancer Res. 2011, 9:1418-1428.
31. Zhao L., Vogt P.K. Class I PI3K in oncogenic cellular transformation. Oncogene 2008, 27:5486-5496.
32. Zhao L., Vogt P.K. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. USA 2008, 105:2652-2657.
33. Zhao Y., Zhang X., Guda K., Lawrence E., Sun Q., Watanabe T., Iwakura Y., Asano M., Wei L., Yang Z., et al. Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proc. Natl. Acad. Sci. USA 2010, 107:2592-2597.